Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
As the company prepares to host its first investor day in over a decade the focus falls on underappreciated in-house assets.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Karyopharm’s newly approved myeloma drug, Xpovio, has shown promise in earlier lines of therapy, but toxicity could still cap its potential.